Overview
- Investors pushed the stock up about 20–22% in premarket trading Wednesday after new 16-week rheumatoid arthritis data for IMVT-1402.
- At the 600 mg weekly dose, 72.7% of patients hit ACR20, 54.5% reached ACR50, and 35.8% achieved ACR70, which reflect at least 20%, 50%, and 70% improvement in tender and swollen joints.
- The study enrolled 170 people who had failed at least two advanced drugs such as JAK inhibitors and anti-TNF therapies, with 165 evaluated at 16 weeks.
- Investigators reported no new safety signals and described the once-weekly shot as safe and well tolerated across the trial.
- Immunovant posted a wider fiscal Q4 loss of $147.9 million, or $0.73 per share, missed estimates, and said cash on hand can support a planned Graves’ disease launch, with a cutaneous lupus study fully enrolled and key readouts expected in the second half of 2026.